United Therapeutics settles patent litigation with Watson Labs; licenses rights to generic Tyvaso
Executive Summary
As part of a patent settlement, United Therapeutics Corp. licensed Watson Laboratories Inc. rights to market a generic version of Tyvaso inhalation solution (treprostinil; marketed for the treatment of pulmonary arterial hypertension) beginning on January 1, 2026. Watson's generics business is part of Teva as Allergan PLC divested the business in July 2015.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Nasal
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice